CLAIMS

1. Use of a combination for the manufacture of a medicament for treating gynaecological diseases and associated disabling symptoms thereof selected from the group comprising uterine fibroid, endometriosis, adenomyosis, excessive uterine bleeding, abnormal uterine bleeding or dysfunctional uterine bleeding uterine endometrial proliferation, uterine bleeding or myoma volume
in a subject in need thereof, said pharmaceutical combination comprising
i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate (CDB-2914) or any metabolite thereof is orally administered, in a therapeutically effective daily amount of 5 to 20 mg.

and
ii) a pharmaceutical composition suitable for vaginal and/ or intrauterine administration wherein ulipristal acetate (CDB-2914) or any metabolite thereof is released at an effective daily release amount of amount of 0.1 to 20 mg.

characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/or intrauterine administration are co-administered, either concomitantly, or separately.

2. The use of claim 1s, wherein the pharmaceutical composition suitable for oral administration is selected from the group comprising dental pastes, tablets, capsules, lozenges, pills, and solutions.

3. The use of any of the preceding claims, wherein the pharmaceutical composition suitable for vaginal and/or intrauterine administration is selected from the group comprising vaginal suppositories, vaginal rings, vaginal gels or foams, vaginal tablet, vaginal insert, vaginal ointment/cream, ovule and intra-uterine delivery systems.

4. The useof claim 1, wherein ulipristal acetate (CDB-2914) or any metabolite thereof is orally administered in a therapeutically effective daily amount of 5 or 10 mg.

5. The use of claim 1, wherein ulipristal acetate (CDB-2914) or any metabolite thereof is orally administered in a therapeutically effective daily amount of 5 mg.

6. The use of claim 1, wherein ulipristal acetate (CDB-2914) or any metabolite thereof suitable for vaginal and/ or intrauterine administration is released at an effective daily release amount of amount of 0.25 to 5 mg.

7. The use of claim 1, wherein ulipristal acetate (CDB-2914) or any metabolite thereof suitable for vaginal and/ or intrauterine administration is released at an effective daily release amount of amount of 1 mg.

8. A use of a combination for the manufacture of a medicament for inhibiting uterine endometrial proliferation in a subject in need thereof, said combination comprising
i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate is orally administered in a therapeutically effective daily amount of 5 to 20 mg and
ii) a pharmaceutical composition suitable for vaginal and/or intrauterine administration wherein ulipristal acetate (CDB-2914) or any metabolite thereof is released at an effective daily release amount of amount of 0.1 to 20 mg characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/or intrauterine administration are co-administered, either concomitantly, or separately.

9. A use of a combination for the manufacture of a medicament for reducing uterine bleeding in a subject in need thereof, said combination comprising
i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate is orally administered in a therapeutically effective daily amount of 5 to 20 mg. comprising a therapeutically effective amount of a first progesterone receptor modulator, or any active metabolite thereof, and
ii) a pharmaceutical composition suitable for vaginal and/ or intrauterine administration wherein ulipristal acetate (CDB-2914) or any metabolite thereof is released at an effective daily release amount of amount of 0.1 to 20 mg
characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/ or intrauterine administration are co-administered, either concomitantly, or separately.

10. A use of a combination for the manufacture of a medicament for reducing myoma volume in a subject in need thereof, said combination comprising

i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate is orally administered in a therapeutically effective daily amount of 5 to 20 mg and

ii) a pharmaceutical composition suitable for vaginal and/or intrauterine administration wherein ulipristal acetate (CDB-2914) or any metabolite thereof is released at an effective daily release amount of amount of 0.1 to 20 mg

characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/ or intrauterine administration are co-administered, either concomitantly, or separately.